PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Clinical trial NCT06530550 · RECRUITING
Trial details
- NCT number
- NCT06530550
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-10
- Primary completion
- 2026-08-10
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.